administrative18.319.921.526.521.522.029.032.4Total non-GAAP operating expenses excluding commissions and other related expense$ 211.2$ 217.4$ 215.0$ 224.4$ 235.4$ 249.9$ 252.4$ 259.0SOURCE COMPASS## 21%[more press release views with Request a Demo]## Also from this source### Compass and Anywhere Real Estate Begin a New Chapter as One Company Built for Real Estate Professionals[Compass, Inc. (NYSE: COMP) announces the completion of its all-stock combination with Anywhere Real Estate Inc. Following the merge ...

Compass and Rocket Form Historic Alliance to Dramatically Increase Home Listing Inventory on Redfin [Accessibility Statement] Skip Navigation--Rocket Companies, Inc. logo (PRNewsfoto/Rocket Companies)Compass International Holdings logo- Integrated search, agent and mortgage experience designed to make the homebuying process straightforward with less friction.- Compass International Holdings' unique inventory to appear on Redfin.com, with the potential to bring more than 500,000 additional home listings to m ...

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the TD Cowen 46th Annual Healthcare Conference in Boston, MA, from March 2-4, 2026 and will participate in a fireside chat on March 3, 2026 at 10:30am ET. A live audio webcast of this event will be accessible from the "Events†page of the Investors section of the C ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares ("ADSs†) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre- funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999. ...

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the launch of a proposed public offering of $150.0 million of American Depositary Shares ("ADSs†), each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase ADSs. All securities are being offered by Compass Pathways. Compass Pathways expe ...

Core Insights - Compass Pathways plc has successfully achieved the primary endpoint in the ongoing Phase 3 COMP006 trial, which is the second of two Phase 3 trials evaluating COMP360 for treatment-resistant depression [1] Group 1 - The trial is assessing two fixed doses of COMP360, a synthetic, proprietary formulation of psilocybin [1] - The primary endpoint focused on the difference in change, indicating a significant milestone in the trial's progress [1]

Core Insights - Compass Pathways plc is set to report new clinical data from two ongoing Phase 3 trials evaluating COMP360, a synthetic formulation of psilocybin for treatment-resistant depression (TRD) [1] Group 1 - The company will disclose new clinical data from Part A and Part B of trial COMP005 and Part A of trial COMP006 [1]

Core Viewpoint - Compass Gold Corporation successfully completed a private placement, raising approximately $5.4 million through the issuance of 28,412,264 units at a price of $0.19 per unit, exceeding the initial target of $5 million due to strong demand [1][2]. Group 1: Offering Details - The offering consisted of units, each comprising one common share and one common share purchase warrant, with warrants exercisable at $0.25 until February 12, 2029 [2]. - The net proceeds will be allocated to the evaluation and establishment of a gold processing facility at the Massala prospect, drilling, metallurgical studies, bulk sampling, and general corporate purposes [3]. Group 2: Agent and Fees - Canaccord Genuity Corp. acted as the sole agent and bookrunner for the offering, receiving a cash commission of 6.0% of the gross proceeds, reduced to 2.0% for units sold to purchasers on the president's list [5]. - The agent was also issued 1,225,020 non-transferable broker warrants, exercisable at $0.19 until February 12, 2028 [5]. Group 3: Insider Participation - Insiders purchased a total of 636,842 units for approximately $121,000, which is classified as a related party transaction [7]. - The participation was exempt from certain valuation and minority shareholder approval requirements due to the company's market capitalization and the nature of the transaction [7]. Group 4: Company Background - Compass Gold is a public company incorporated in Ontario and is a Tier 2 issuer on the TSX-V, holding gold exploration permits in Mali with a combined area of approximately 900 square kilometers [10]. - The company's exploration permits are located in a region known for several multi-million-ounce gold projects, indicating potential for significant resource development [10].

Core Insights - Compass, Inc. will release its fourth quarter and full-year 2025 financial results on February 26, 2026, after market close, followed by a conference call at 5:00 p.m. ET [1] - The company operates as a global real estate services provider with a presence in major U.S. cities and approximately 120 countries, serving millions of buyers and sellers through well-known brands [1][2] Company Overview - Compass, Inc. empowers over 300,000 real estate professionals through its owned-brokerage and franchise business, enhancing service delivery to consumers [1] - The company offers a range of integrated services beyond brokerage, including mortgage, title, insurance, escrow, and relocation [2] Investor Relations - The company utilizes its Investor Relations website to disclose material information and comply with regulatory obligations, encouraging investors to monitor updates through various channels [3] - The upcoming conference call and shareholder presentation will be accessible online, with a replay available for 90 days post-call [4]

Core Viewpoint - The comparison between Compass Group PLC (CMPGY) and Dutch Bros (BROS) indicates that CMPGY presents a better value opportunity for investors at this time due to its stronger earnings outlook and more attractive valuation metrics [1][3][7]. Valuation Metrics - CMPGY has a forward P/E ratio of 19.80, significantly lower than BROS's forward P/E of 61.16, suggesting that CMPGY is more reasonably priced relative to its earnings [5]. - The PEG ratio for CMPGY is 1.73, while BROS has a PEG ratio of 1.98, indicating that CMPGY's expected earnings growth is more favorable compared to its price [5]. - CMPGY's P/B ratio stands at 6.41, compared to BROS's P/B of 9.97, further highlighting CMPGY's relative undervaluation [6]. Investment Ratings - CMPGY holds a Zacks Rank of 2 (Buy), indicating a positive outlook, while BROS has a Zacks Rank of 4 (Sell), suggesting a less favorable investment position [3][7]. - The Value grade for CMPGY is B, reflecting its strong valuation metrics, whereas BROS has a Value grade of F, indicating poor valuation [6].